Advanced Search

Home > Journals > Minerva Biotecnologica > Past Issues > Minerva Biotecnologica 2008 September;20(3) > Minerva Biotecnologica 2008 September;20(3):133-5



A Journal on Biotechnology and Molecular Biology

Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,246

Frequency: Quarterly

ISSN 1120-4826

Online ISSN 1827-160X


Minerva Biotecnologica 2008 September;20(3):133-5


A simultaneous dual-isotope acquisition and imaging fusion protocol in nuclear medicine: 111In-Octreotide SPECT and 99mTc-HMDP bone SPECT

Zanotti-Fregonara P. 1, Keller I. 2, Devaux J.-Y. 2, Massaro A. 3, Rubello D. 3, Hindié E. 4

1 DSV/IBM/SHFJ/LIME Commissariat à l’Energie Atomique, Orsay, France
2 Service de Médecine Nucléaire Hôpital St Antoine, Paris, France
3 Department of Nuclear Medicine PET Center, S. Maria della Misericordia Hospital, Rovigo, Italy
4 Service de Médecine Nucléaire, Hôpital St Louis, Paris, France

In the present preliminary study, we developed a protocol for the acquisition and fusion of dual-isotope tomographic (SPECT) images (111In-Octreotide SPECT and 99mTc-HMDP SPECT). This procedure was performed in ten consecutive patients, and the first results were encouraging: it proved to be a simple and accurate method to improve the anatomic localization of 111In-Octreotide SPECT positive foci for the staging and follow-up of tumours expressing somatostatin receptors (Octreotide is an analog of somatostatin), particularly in discriminating bone metastases from soft tissue metastases located near to bone itself.

language: English


top of page